The CDMO will manufacture raw materials for the clinical development of DNV001, a novel therapy for the treatment of dyslipidaemia
By combining technologies, the companies hope to optimise the cell assay development workflow with automation
Get breaking news, product releases, technical papers, innovation features, trend reports and live content agendas covering the entire industry.